CLOs on the Move

Bruce McGaw Graphics (CDA)

www.bmcgaw.ca

 
Bruce McGaw Graphics (CDA) is a Saint-Laurent, QC-based company in the Business Services sector.
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million
  • www.bmcgaw.ca

  • Saint-Laurent, QC CAN H4S 1E5
  • Phone: 514.856.0650

Executives

Name Title Contact Details

Similar Companies

3Aware

3Aware supports immediate access to real-world clinical data for medical device manufacturers in a self-administered platform. MedTech Clinical and Regulatory teams spend exorbitant time and money on the real-world data collection to support keeping devices on the market. With a host of patchwork solutions, there remains no solution to meet their clinical data needs reliably, quickly and affordably. The 3Aware solution provides immediate Access to real world data for device encounters, the ability to Analyze the data for inclusion/ exclusion for PMCF reporting and Alerts to safety and performance of devices. Our solution saves Medtech time and money spent on clinical data acquisition for the purpose of Post Market Surveillance.

First Contact HR

First Contact HR is a Fort Washington, PA-based company in the Business Services sector.

Global Technology SaaS

Our Network of Founding Members consist of Master of Scientist Electrical Engineers, Data Scientists, MBAs, and Business Development executives all former C-Level members of large multinational corporations. We have deep domain expertise in Telecom Ecosystems, Network Virtualization, Hardware and Software System Architecture, and a data driven system to assess your products and best use case.

DRI Healthcare

DRI Healthcare is a pioneer in global pharmaceutical royalty monetization. Over the course of three decades, we have been a trusted partner of royalty sellers and demonstrated strong execution, building a diversified portfolio of interests in medicines that have a demonstrable positive impact on the world. That foundation sets us apart as we continue developing solutions for innovators while building and managing a risk-mitigated portfolio of therapeutic assets that generates attractive returns and growth potential for investors. We have deployed more than $2.5 billion, acquiring more than 70 royalties on 40-plus drugs.